LEQLUZO
Live / Applied — Fourth extension granted (statement of use) (as of 09 Sept 2025)
What this means for you
Not registered yet, but its 30 Aug 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97571126
- Mark type
- Stylized text
- Filed
- 30 Aug 2022
- Published for opposition
- 18 Jul 2023
- Attorney of record
- Cheryl L. Foytlin
Goods and services
- Class 005 — Pharmaceuticals: Human pharmaceutical preparations for the prevention and treatment of viral diseases, auto-immune and inflammatory diseases, cardiovascular and pulmonary diseases, central nervous system diseases, peripheral neurological system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, digital ulcers, and cerebrovascular diseases; vaccines; anxiolytics; anti-allergics; anti-infectives
Owner
- Johnson & Johnson, New Brunswick, NJ, US
- Johnson & Johnson, New Brunswick, NJ, US
Prosecution history
- 10 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 Sept 2025 — SOU EXTENSION 4 GRANTED
- 09 Sept 2025 — SOU EXTENSION 4 FILED
- 09 Sept 2025 — SOU TEAS EXTENSION RECEIVED
- 25 Feb 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 25 Feb 2025 — SOU EXTENSION 3 GRANTED
- 24 Feb 2025 — SOU EXTENSION 3 FILED
- 24 Feb 2025 — SOU TEAS EXTENSION RECEIVED
- 15 Aug 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 15 Aug 2024 — SOU EXTENSION 2 GRANTED
- 15 Aug 2024 — SOU EXTENSION 2 FILED
- 15 Aug 2024 — SOU TEAS EXTENSION RECEIVED
- 24 Feb 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 23 Feb 2024 — SOU EXTENSION 1 GRANTED
- 23 Feb 2024 — SOU EXTENSION 1 FILED